7ZF7
| SARS-CoV-2 Omicron BA.2 RBD in complex with ACE2 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Processed angiotensin-converting enzyme 2, Spike protein S1, ... | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | Deposit date: | 2022-04-01 | Release date: | 2022-06-01 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (3.46 Å) | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 185, 2022
|
|
7ZF5
| SARS-CoV-2 Omicron RBD in complex with Omi-12 and Beta-54 Fabs | Descriptor: | Beta-54 heavy chain, Beta-54 light chain, Omi-12 heavy chain, ... | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | Deposit date: | 2022-04-01 | Release date: | 2022-06-01 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (5.32 Å) | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 185, 2022
|
|
7ZF3
| SARS-CoV-2 Omicron RBD in complex with Omi-3 and EY6A Fabs | Descriptor: | EY6A heavy chain, EY6A light chain, GLYCEROL, ... | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | Deposit date: | 2022-04-01 | Release date: | 2022-06-01 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (3.15 Å) | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 185, 2022
|
|
7ZF4
| SARS-CoV-2 Omicron RBD in complex with Omi-9 Fab and nanobody F2 | Descriptor: | Nanobody F2, Omi-9 heavy chain, Omi-9 light chain, ... | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | Deposit date: | 2022-04-01 | Release date: | 2022-06-08 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (4.18 Å) | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 185, 2022
|
|
7ZFA
| SARS-CoV-2 Omicron RBD in complex with Omi-6 and COVOX-150 Fabs | Descriptor: | COVOX-150 heavy chain, COVOX-150 light chain, Omi-6 heavy chain, ... | Authors: | Zhou, D, Huo, J, Ren, J, Stuart, D.I. | Deposit date: | 2022-04-01 | Release date: | 2022-06-29 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (4.24 Å) | Cite: | Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 185, 2022
|
|